AstraZeneca has been removed from Denmark’s COVID-19 vaccine program, and this was officially announced on Wednesday, April 14. With this decision, the region became the first country to completely abandon this brand of coronavirus shots.
Delayed vaccination schedule
As per Reuters, the move will put off Denmark’s scheduled completion of its AstraZeneca vaccination scheme that was initially set to July 25. The new date has been moved to early August, according to health authorities.
This means that everyone who already has vaccination appointments for AstraZeneca vaccine shots will be canceled and rescheduled. For those who have received the first dose, they will not be getting the pulled-out vaccine anymore, but a new brand will be administered as a second dose.
It was added that those who are 16 years old and above could expect to get an offer for vaccination in late June. The individuals who will accept the offer will be inoculated five weeks later, which is in early August.
Why Denmark ditches AstraZeneca
The Danish Health Authority released a statement and cited rare side effects and others as reasons for the decision to stop administering the AstraZeneca vaccine to the citizens. The agency further explained that while the benefits o- taking the shots outweigh the risks, they still chose to discontinue due to the possible link to rare cases of blood clotting. The health authority added that other vaccines are also available in Denmark, so they could just use this.
"Based on the scientific findings, our overall assessment is there is a real risk of severe side effects associated with using the COVID-19 vaccine from AstraZeneca," DHA’s director-general, Søren Brostrøm, said. "We have, therefore, decided to remove the vaccine from our vaccination program."
He went on to explained, "In the midst of an epidemic, it has been a difficult decision to continue our vaccination program without an effective and readily available vaccine against COVID-19. However, we have other vaccines at our disposal, and the epidemic is currently under control.
Once the administration of COVID-19 vaccines starts again in Denmark, it was said that the Johnson & Johnson brand would be used. In any case, this vaccine was rolled out in Europe and got delayed due to reports of the same blood clotting that was said to have developed in some people who had the AstraZeneca vaccine.


U.S. Stock Futures Rise as Markets Brace for Jobs and Inflation Data
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
Washington Post Publisher Will Lewis Steps Down After Layoffs
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
Australian Household Spending Dips in December as RBA Tightens Policy
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 



